FDA vs CE vs NMPA: Navigating Medical Device Regulations for Silicone Products

If you're selling medical devices containing silicone components, you're probably dealing with—or will need to deal with—multiple regulatory frameworks. The FDA, EU MDR, and China's NMPA each have their own requirements, procedures, and philosophies.

Let's cut through the confusion and give you a practical comparison of how these three major regulatory systems handle silicone medical devices.

The Big Picture

Before diving into specifics, here's an overview of how these systems differ in their approach:

FDA (United States): Performance-based regulation with post-market emphasis. The FDA sets requirements but relies heavily on industry self-certification and post-market surveillance.

CE Marking / EU MDR (European Union): Risk-based regulation with pre-market scrutiny. The MDR requires comprehensive technical documentation and ongoing clinical evidence.

NMPA (China): Increasingly harmonizing with international standards but maintains distinct procedures, testing requirements, and local considerations.

FDA Requirements for Silicone Medical Devices

Classification System

The FDA classifies devices into three classes based on risk:

Class I (Low Risk): General controls, most are exempt from premarket review

Class II (Moderate Risk): General controls plus special controls, typically requires 510(k)

Class III (High Risk): Premarket approval (PMA) required

Most silicone components for medical devices fall into Class I or II, meaning 510(k) clearance is often the pathway. However, devices with prolonged tissue contact or critical functionality may be Class III.

The 510(k) Process

For most silicone devices, you'll need to submit a 510(k) demonstrating "substantial equivalence" to a legally marketed predicate device. This requires:

Device Description: Comprehensive description of the silicone device, materials, dimensions, and manufacturing process.

Predicate Comparison: Comparison to a legally marketed device showing similar intended use and technological characteristics.

Biocompatibility Documentation: Per ISO 10993 series, with testing appropriate to tissue contact duration and type.

Manufacturing Information: Brief description of manufacturing processes and quality system overview.

Labeling: Complete labeling with intended use statements.

The FDA aims to review 510(k)s within 90 days, but actual timelines often run 6-12 months or longer depending on submission quality and FDA workload.

Quality System Requirements

Under 21 CFR Part 820 (Quality System Regulation, or QSR), manufacturers must establish and maintain quality systems covering:

• Design controls

• Production and process controls

• Corrective and preventive action (CAPA)

• Document and records control

• Complaint handling

The FDA increasingly expects compliance aligned with ISO 13485, even though the regulations differ somewhat in specifics.

Key Considerations for FDA Submissions

Predicate Selection: Finding an appropriate predicate device can be challenging for novel silicone applications. A good regulatory strategy considers predicate availability early.

Biocompatibility Testing: The FDA strongly prefers direct testing per ISO 10993 rather than literature citations. Plan for 3-6 months of biocompatibility testing.

Manufacturing Changes: Any significant changes to silicone formulation, manufacturing process, or supplier require review. Establish change control procedures.

CE Marking Under EU MDR

The MDR 2017/745 Framework

Since May 2021, all medical devices sold in the EU must comply with the Medical Device Regulation (MDR) 2017/745, which replaced the older Medical Device Directive (MDD). The MDR significantly increased requirements, especially for:

Technical Documentation: Comprehensive documentation covering device description, design and manufacturing information, risk analysis, clinical evaluation, and post-market surveillance plans.

Clinical Evidence: Stronger requirements for clinical data to support safety and performance claims. Many devices previously certified under MDD now face gaps requiring additional clinical evidence.

Post-Market Surveillance: Ongoing requirements to collect and analyze post-market data, including periodic safety update reports (PSURs).

Classification Under MDR

The MDR uses classification rules that often result in higher classifications than the old MDD. Most silicone medical devices fall into:

Class I: Low risk, self-certification possible (but must register)

Class IIa: Moderate risk, requires notified body assessment

Class IIb: Higher moderate risk, requires notified body assessment

Class III: High risk, requires intensive notified body review

The Conformity Assessment Route

For most silicone devices requiring notified body involvement, you'll follow either:

Annex IX (Quality management and clinical evaluation): Assessment of QMS and clinical evaluation documentation.

Annex XI (Production quality assurance): Assessment of production quality assurance processes.

The choice depends on device classification and manufacturer preferences.

Biocompatibility Under MDR

MDR requires compliance with ISO 10993 for biocompatibility, similar to FDA requirements. However, MDR also requires:

Chemical Characterization: Detailed chemical analysis of all constituents that could migrate from the silicone material.

Risk Assessment: Systematic evaluation of identified substances for potential harm.

Re-evaluation Triggers: Changes in material composition or processing require re-evaluation of biocompatibility.

Key Challenges with MDR

Notified Body Capacity: The transition to MDR revealed significant bottlenecks in notified body capacity. Lead times for new certifications have stretched considerably.

Clinical Evidence Requirements: The MDR's emphasis on clinical evidence has caught many manufacturers unprepared, especially those who relied on equivalence to support their CE marking under MDD.

EUDAMED Registration: The new European database requires registration and ongoing reporting, with phased implementation.

NMPA Requirements (China)

Regulatory Evolution

China's NMPA (formerly CFDA) has been modernizing its regulatory framework, moving toward greater harmonization with international standards while maintaining distinct requirements.

The revised Medical Device Regulations (State Council Order 739) and associated registration procedures govern device approval in China.

Classification

NMPA uses a classification system with four classes:

Class I: Simple registration, local NMPA filing

Class II: Provincial-level registration with technical review

Class III: National-level registration with NMPA central review

Most silicone medical devices fall into Class II or III, requiring formal registration.

Registration Process

Class II Devices:

1. Compile Chinese-language technical documentation

2. Submit to provincial NMPA

3. Technical review and testing at designated laboratories

4. Approval and certificate issuance

Class III Devices:

1. Compile documentation per NMPA requirements

2. Submit to NMPA Center for Medical Device Evaluation

3. Technical review with potential expert panel review

4. Testing at NMPA-designated testing laboratories

5. On-site inspection of manufacturing facilities

6. Approval

Timelines vary significantly: Class II registration typically takes 12-18 months; Class III can take 2-3 years or longer.

Unique NMPA Requirements

Chinese Standards (YY/T): NMPA may require testing per specific Chinese standards, which may differ from ISO equivalents. These must be identified early in planning.

Testing Laboratory Requirements: Testing must be performed at NMPA-designated testing laboratories, not just any ISO/IEC 17025 accredited lab.

Manufacturing Site Inspection: For Class III devices, NMPA typically conducts on-site inspections of the manufacturing facility as part of registration.

Local Representative: Foreign manufacturers must designate a Chinese agent to handle regulatory affairs.

Chinese Language Documentation: All submitted documentation must be in Chinese (or include certified Chinese translations).

Recent Developments

NMPA has been working to:

• Streamline registration procedures

• Accept foreign clinical data more readily

• Establish mutual recognition agreements with other regulatory bodies

• Implement unique device identification (UDI) requirements

Comparing Key Requirements Side-by-Side

Practical Strategies for Multi-Market Access

Start with the Most Stringent Requirements

Given that requirements overlap significantly, design your regulatory strategy around the most demanding market (often EU MDR for comprehensive documentation). Building to MDR standards typically means FDA and NMPA submissions are also achievable.

Leverage International Standards

ISO 10993, ISO 13485, and related standards provide a common foundation recognized across all three regulatory systems. Invest in compliance with these standards early.

Plan for Testing Early

Biocompatibility testing typically requires 3-6 months. Build this into your project timeline and consider parallel testing across multiple endpoints to accelerate the process.

Maintain Comprehensive Documentation

Documentation prepared for one regulatory submission should be structured to support others. A well-organized technical file can often be adapted for multiple markets.

Choose Suppliers with Multi-Market Experience

Your silicone component supplier should understand regulatory requirements across markets. At Chensheng Medical, we support customers pursuing FDA, CE, and NMPA registration with:

• Complete biocompatibility documentation

• Quality system certifications (ISO 13485)

• Technical documentation packages

• Manufacturing process validation

• Change notification and control

Consider Professional Support

Regulatory submissions in multiple jurisdictions benefit from professional support. Regulatory affairs consultants with specific market expertise can navigate nuances and avoid costly delays.

Common Pitfalls to Avoid

Underestimating Timeline: All three systems take longer than initial expectations suggest. Build in buffer time.

Inadequate Biocompatibility Documentation: Don't assume past testing is sufficient. Tissue contact type and duration must be re-evaluated for each device.

Change Control Neglect: Even approved devices require change control procedures. A formulation tweak by your silicone supplier can trigger regulatory obligations.

Incomplete Labeling: Each market has specific labeling requirements. "FDA cleared" labeling is not "CE marked" labeling.

Documentation Language: All three systems require documentation in their official language (or certified translations for NMPA). Plan for translation costs and timelines.

The Bottom Line

Navigating FDA, CE, and NMPA requirements for silicone medical devices requires careful planning, substantial documentation, and ongoing attention to regulatory compliance. But with the right approach and qualified partners, multi-market access is achievable.

Focus on building a strong quality system foundation, invest in comprehensive biocompatibility testing, and maintain rigorous change control procedures. These fundamentals serve you well regardless of which regulatory systems you're targeting.

Need help understanding how these requirements apply to your specific silicone medical device? We're happy to discuss your regulatory strategy and how we can support your market access goals.

Need Assistance with Regulatory Compliance for Your Silicone Medical Devices?

Navigating the complexities of FDA, CE, and NMPA regulations can be challenging. At Chensheng Medical, we provide expert guidance to help you understand and meet these requirements effectively.

Contact Us to discuss your regulatory strategy and learn how we can support your market access goals.

You can also explore more insights on our Blog.

Author: Robert Chen, Director of Regulatory Affairs at Chensheng Medical

Robert has guided over 200 medical device products through FDA, CE, and international regulatory approvals, specializing in silicone-based devices and combination products.